Aroa Biosurgery
ARXAuckland, New Zealand· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileARX · Stock Price
USD 15.91+2.74 (+20.80%)
Market Cap: $1.8B
Historical price data
Overview
Aroa Biosurgery commercialises ECM‑based scaffolds for soft‑tissue repair and wound healing, leveraging a proprietary ruminant ECM platform.
Soft Tissue RepairWound ManagementSurgical Reconstruction
Technology Platform
Proprietary ruminant forestomach extracellular matrix (ECM) scaffolds that retain native collagen, growth factors, and structural proteins to support natural tissue regeneration.
Opportunities
Expansion into European and Asian markets, broader reimbursement adoption, and development of next‑generation ECM therapies for orthopedic and cardiovascular indications.
Risk Factors
Regulatory and reimbursement uncertainties, competition from larger medtech firms, and reliance on a limited product portfolio.
Competitive Landscape
Competes with biologic mesh and wound‑care leaders such as Integra LifeSciences, Smith & Nephew, and Medtronic, differentiating through its proprietary ruminant ECM platform and integrated product suite.